Special Issue "Recent Advances and Future Approaches in Preventive and Therapeutic Effects of Vanadium Complexes"
Deadline for manuscript submissions: 29 December 2023 | Viewed by 579
Interests: vanadium complexes; plant compounds; anticancer agents; acute leukemia
Interests: metabolic activity of the brain's diseases like neuropsychiatric, stroke; redox signaling, tooth decay, biostatistics, biomaterials; composites; drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Vanadium is a trace element of interest due to the therapeutic properties of its organic and inorganic complexes. Vanadium can have a Lewis acid character and occurs in a variety of oxidative states, the most common of which are the tetravalent and pentavalent forms. Its high reactivity is used to form various inorganic and organic compounds. Because transition metal compounds can reduce toxicity and improve bioavailability of free organic ligands and the elements themselves, they are being investigated for applications in the treatment of many diseases. Vanadium is characterized by nephrotoxicity, as demonstrated in in vivo studies. Therefore, metallodrugs with less toxicity than the element itself are sought in vanadium complexes, especially organic ones.
Vanadium complexes may have potential therapeutic applications in the treatment of type 2 diabetes, cancer or infection diseases. Vanadium's activity mimics that of phosphates, so it can modify the action of kinases and phosphatases, which explains its antidiabetic, anticancer, cardioprotective, and antimicrobial effects.
This Special Issue aims to present research on new vanadium complexes with protective effects against metabolic disorders, with antidiabetic or antiobesity activity. Work on other potential therapeutic applications of vanadium compounds, such as anticancer, antimicrobial, cardioprotective, and neuroprotective properties not yet demonstrated in research, will also be well received.
Dr. Monika A. Papież
Dr. Wirginia Krzyściak
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- vanadium compounds
- antidiabetic, insulinomimetic